ReviewInternational journal of rheumatology2021
Update in the Management of ANCA-Associated Vasculitis: Recent Developments and Future Perspectives.
Review in International journal of rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial.Rheumatology (Oxford, England) · 2025Trial
- Refractory Gingival Enlargement: A Critical Oral Clue to Early-Stage Granulomatosis With Polyangiitis-A Case Report and Literature Review.Case reports in dentistry · 2026Article
- Review
- Advances in Multitarget Therapeutic Approaches for Immune-Mediated Glomerular Diseases.Life (Basel, Switzerland) · 2025Article
- Complement as a major mediator of ANCA vasculitis and a target for precision therapy.Expert review of clinical immunology · 2025Review
- Fatal outcome in isolated Pauci-immune pulmonary capillaritis: A case report.Respirology case reports · 2024Article
- A Refractory Case of Rapidly Progressive Glomerulonephritis Due to Microscopic Polyangiitis.Cureus · 2024Article
- Evolution of therapeutic management of patients with ANCA associated vasculitis in France after licensing Rituximab use.BMC rheumatology · 2024Article
- Predictors of medications-free and long-term remission in anti-neutrophil cytoplasmic antibody-associated vasculitis: Real-world evidence.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2024Article
- Low levels of complement factor C3 at diagnosis can predict outcome in antineutrophil antibody associated vasculitis.Journal of nephrology · 2023Article
- Optimal management of ANCA-associated vasculitis before and during pregnancy: current perspectives.Archives of gynecology and obstetrics · 2023Review
- Unmet needs in ANCA-associated vasculitis: Physicians' and patients' perspectives.Frontiers in immunology · 2023Review
- Granulomatosis with Polyangiitis following COVID-19 in an Adolescent.Internal medicine (Tokyo, Japan) · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Significant progress has been made in the treatment of ANCA-associated vasculitides (AAV), notably in granulomatosis with polyangiitis and microscopic polyangiitis. Over the past few years, many innovative studies have changed the way we now induce and maintain remission in AAV; achieving remission while limiting treatment toxicity is the key. This article provides an in-depth, up-to-date summary of recent trials and suggests treatment algorithms for induction and maintenance of remission based on the latest guidelines. Future possible therapies in AAV will also be discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.